EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Influence of C YP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole

Cécile Gras, Marianna Piras, Setareh Ranjbar, Claire Grosu, François R Girardin, Frederik Vandenberghe, Nicolas Ansermot, Carole Grandjean, Stefan Kaiser, Franziska Gamma, Kerstin Jessica Plessen, Armin von Gunten und 3 weitere

Schizophrenia Bulletin · 07.03.2026 · 52 (2)

DOI: 10.1093/schbul/sbaf076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Schizophrenia Bulletin, online erschienen am 14.07.2025. Verfasst von Cécile Gras und 14 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital…. Hauptthemen laut MEDLINE: Aripiprazole, Cytochrome P-450 CYP2D6, Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The antipsychotic aripiprazole is mainly metabolized by the cytochrome P450 (CYP) 2D6. The main objective of this study was to evaluate the influence of CYP2D6 phenotypes on aripiprazole plasma levels and treatment duration.

Design

466 patients treated with aripiprazole for up to 12 months and with at least one aripiprazole plasma level in steady-state condition were selected. CYP2D6 genotypes and phenoconversion to poor metabolizer status due to strong CYP2D6 inhibition were considered. Aripiprazole plasma level-to-dose ratios and treatment duration up to discontinuation, defined as switching to another psychotropic drug and/or stopping the follow-up, were analyzed using robust linear models and Cox regression, respectively. Akaike variable selection was applied.

Results

CYP2D6 poor metabolizers (genetically determined n = 19 and phenoconverted, n = 52) showed higher aripiprazole concentration-to-dose (P < .001) and aripiprazole plus dehydroaripiprazole concentration-to-dose (P < .001) ratios when compared to normal metabolizers (n = 255). CYP2D6 extreme metabolizers (ie, poor and ultrarapid metabolizers) had higher risk of treatment discontinuation versus intermediate and normal metabolizers after 3, 6, and 12 months of treatment (HR: 2.08, 1.75, 1.59, respectively; P = .013, P = .019, and P = .047, respectively). For a pharmacogenetic-guided treatment, the number of patients needed to genotype to prevent 1 patient from aripiprazole discontinuation was 15.

Conclusion

CYP2D6 poor metabolism was associated with increased aripiprazole and aripiprazole plus dehydroaripiprazole concentrations-to-dose. CYP2D6 extreme phenotypes were associated with increased risk of treatment discontinuation over 1 year of treatment. This finding supports the applicability of pre-emptive CYP2D6 genotyping, which is expected to decrease aripiprazole adverse events and inefficacy that would probably lead to treatment discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AripiprazoleCytochrome P-450 CYP2D6Antipsychotic AgentsSchizophreniaHumansMaleAdultFemaleMiddle AgedPhenotypeGenotypeQuinolonesYoung AdultFollow-Up StudiesPiperazines

Stichwörter der Autor:innen

CYP2D6aripiprazolegenetic polymorphismsphenotypepre-emptive genotyping

Substanzen

AripiprazoleCytochrome P-450 CYP2D6Antipsychotic AgentsQuinolonesdehydroaripiprazolePiperazines

Autor:innen und Institutionen

  • Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
  • Montpellier University Hospital, Faculty of Pharmacy-University of Montpellier, Montpellier, France.
  • Center for Psychiatric Epidemiology and Psychopathology, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland.
  • Service of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Adult Psychiatry Division, Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
  • Les Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland.

Förderung

  • National Research Foundation

Zitieren

APA

Gras, C., Piras, M., Ranjbar, S., Grosu, C., Girardin, F. R., Vandenberghe, F., Ansermot, N., Grandjean, C., Kaiser, S., Gamma, F., Plessen, K. J., von Gunten, A., Conus, P., Crettol, S., & Eap, C. B. (2026). Influence of C YP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole. Schizophrenia Bulletin, 52(2). https://doi.org/10.1093/schbul/sbaf076

Vancouver

Gras C, Piras M, Ranjbar S, Grosu C, Girardin FR, Vandenberghe F, et al. Influence of C YP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole. Schizophrenia Bulletin. 2026;52(2). doi:10.1093/schbul/sbaf076

BibTeX
@article{Gras2026,
  author = {Gras, Cécile and Piras, Marianna and Ranjbar, Setareh and Grosu, Claire and Girardin, François R and Vandenberghe, Frederik and Ansermot, Nicolas and Grandjean, Carole and Kaiser, Stefan and Gamma, Franziska and Plessen, Kerstin Jessica and von Gunten, Armin and Conus, Philippe and Crettol, Séverine and Eap, Chin B},
  title = {Influence of C YP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole},
  journal = {Schizophrenia Bulletin},
  year = {2026},
  volume = {52},
  number = {2},
  doi = {10.1093/schbul/sbaf076}
}
Kostenlos starten →